Related Experiment Video
Updated: Jun 12, 2025
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients
Felix Pavlotsky1,2, Zvi Segal1,2, Aviv Barzilai1,2
1Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Background:
Data regarding anti-COVID-19 vaccination efficacy in psoriasis patients treated with immune-modulatory medications are scarce.
Objective:
This study aims to examine the rate of positive antibody response following BNT162b2 vaccine in those patients.
Methods:
BNT162b2-vaccinated and immune modifier-treated psoriatic patients were assigned to serological testing of IgG antibodies to protein S of SARS-CoV-2 after the second vaccination dose by Abbott Architect or Beckman Coulter. Levels ≥ 1 S1 units/mL (S/ml) and > 150 arbitrary units/ml (AU/ml) are considered a positive antibody response, respectively. The antibody levels further analyzed according to the patient's characteristics and compared to health workers' controls.
Results:
Forty-nine of the 51 patients had a positive antibody response. Overall, patients treated with immune-modulatory medications had antibody levels similar to the control group.
Conclusions:
Immune modifier-treated psoriasis patients seem to develop a positive antibody response to the full BNT162b2 vaccination in the vast majority of cases.
Related Concept Videos
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
00:42Cross-reactivity